J.P. Morgan analyst Anupam Rama maintained a Buy rating on BridgeBio Pharma today and set a price target of $70.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anupam Rama has given his Buy rating due to a combination of factors that highlight BridgeBio Pharma’s promising future. The company is poised for significant growth with pivotal data readouts expected in Fall 2025 for its key programs, encaleret for ADH1 and BBP-418 for LGMD2I/R9. These updates are anticipated to act as major catalysts, potentially driving the stock price higher given the high probability of positive outcomes based on prior data.
Anupam Rama’s confidence is further bolstered by BridgeBio’s strong pipeline and the expected successful launch of Attruby. The company’s focus on therapies for Mendelian diseases and cancers with clear genetic drivers positions it well in the biotech industry. The analyst’s valuation reflects a potential increase in share price to the mid-$60s to low-$70s range, supported by the company’s strategic developments and upcoming catalysts.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BBIO in relation to earlier this year.